Cargando…

Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy

Advanced therapies for patients with mild-to-severe ulcerative colitis (UC) may result in treatment failure. We examined whether the lymphocyte-to-monocyte ratio (L/M ratio) could predict the failure of advanced therapies. This retrospective, observational, cohort study included 73 patients who were...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Natsuki, Asai, Yusuke, Miyazu, Takahiro, Tamura, Satoshi, Tani, Shinya, Yamade, Mihoko, Iwaizumi, Moriya, Hamaya, Yasushi, Osawa, Satoshi, Furuta, Takahisa, Sugimoto, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178621/
https://www.ncbi.nlm.nih.gov/pubmed/35692303
http://dx.doi.org/10.1093/gastro/goac025
_version_ 1784723100480307200
author Ishida, Natsuki
Asai, Yusuke
Miyazu, Takahiro
Tamura, Satoshi
Tani, Shinya
Yamade, Mihoko
Iwaizumi, Moriya
Hamaya, Yasushi
Osawa, Satoshi
Furuta, Takahisa
Sugimoto, Ken
author_facet Ishida, Natsuki
Asai, Yusuke
Miyazu, Takahiro
Tamura, Satoshi
Tani, Shinya
Yamade, Mihoko
Iwaizumi, Moriya
Hamaya, Yasushi
Osawa, Satoshi
Furuta, Takahisa
Sugimoto, Ken
author_sort Ishida, Natsuki
collection PubMed
description Advanced therapies for patients with mild-to-severe ulcerative colitis (UC) may result in treatment failure. We examined whether the lymphocyte-to-monocyte ratio (L/M ratio) could predict the failure of advanced therapies. This retrospective, observational, cohort study included 73 patients who were treated with advanced therapies at the Hamamatsu University School of Medicine (Shizuoka, Japan) between February 2011 and November 2020. The patients were divided into the non-failure and failure groups, and their leukocyte counts and ratios before induction were examined. Univariate and multivariate analyses were performed to identify the prognostic factors. Advanced therapies failed within 3 months in 15 (20.5%) patients. Only the L/M ratio was significantly lower in the failure group than in the non-failure group (P = 0.004). Receiver-operating characteristic (ROC) curve analysis revealed that an L/M ratio of ≤3.417 was predictive of treatment failure; the area under the curve (AUC) was 0.747 (95% CI, 0.620–0.874). Kaplan–Meier analysis revealed that the failure-free rate was significantly lower in the group with an L/M ratio of ≤3.417 than in the group with an L/M ratio of >3.417 (log-rank test P = 0.002). Cox proportional hazard regression analysis identified an L/M ratio of ≤3.417 as an independent risk factor for failure within 3 months after the induction of advanced therapies. Furthermore, ROC analysis of patients who did not receive immunomodulators also revealed that the cut-off L/M ratio was 3.417 and the AUC was 0.796 (95% CI, 0.666–0.925). In patients receiving advanced therapies for active UC, the L/M ratio can predict treatment failure within 3 months. L/M ratios could facilitate the transition from advanced therapies to subsequent treatments.
format Online
Article
Text
id pubmed-9178621
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91786212022-06-09 Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy Ishida, Natsuki Asai, Yusuke Miyazu, Takahiro Tamura, Satoshi Tani, Shinya Yamade, Mihoko Iwaizumi, Moriya Hamaya, Yasushi Osawa, Satoshi Furuta, Takahisa Sugimoto, Ken Gastroenterol Rep (Oxf) Original Article Advanced therapies for patients with mild-to-severe ulcerative colitis (UC) may result in treatment failure. We examined whether the lymphocyte-to-monocyte ratio (L/M ratio) could predict the failure of advanced therapies. This retrospective, observational, cohort study included 73 patients who were treated with advanced therapies at the Hamamatsu University School of Medicine (Shizuoka, Japan) between February 2011 and November 2020. The patients were divided into the non-failure and failure groups, and their leukocyte counts and ratios before induction were examined. Univariate and multivariate analyses were performed to identify the prognostic factors. Advanced therapies failed within 3 months in 15 (20.5%) patients. Only the L/M ratio was significantly lower in the failure group than in the non-failure group (P = 0.004). Receiver-operating characteristic (ROC) curve analysis revealed that an L/M ratio of ≤3.417 was predictive of treatment failure; the area under the curve (AUC) was 0.747 (95% CI, 0.620–0.874). Kaplan–Meier analysis revealed that the failure-free rate was significantly lower in the group with an L/M ratio of ≤3.417 than in the group with an L/M ratio of >3.417 (log-rank test P = 0.002). Cox proportional hazard regression analysis identified an L/M ratio of ≤3.417 as an independent risk factor for failure within 3 months after the induction of advanced therapies. Furthermore, ROC analysis of patients who did not receive immunomodulators also revealed that the cut-off L/M ratio was 3.417 and the AUC was 0.796 (95% CI, 0.666–0.925). In patients receiving advanced therapies for active UC, the L/M ratio can predict treatment failure within 3 months. L/M ratios could facilitate the transition from advanced therapies to subsequent treatments. Oxford University Press 2022-06-08 /pmc/articles/PMC9178621/ /pubmed/35692303 http://dx.doi.org/10.1093/gastro/goac025 Text en © The Author(s) 2022. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Ishida, Natsuki
Asai, Yusuke
Miyazu, Takahiro
Tamura, Satoshi
Tani, Shinya
Yamade, Mihoko
Iwaizumi, Moriya
Hamaya, Yasushi
Osawa, Satoshi
Furuta, Takahisa
Sugimoto, Ken
Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title_full Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title_fullStr Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title_full_unstemmed Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title_short Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
title_sort lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178621/
https://www.ncbi.nlm.nih.gov/pubmed/35692303
http://dx.doi.org/10.1093/gastro/goac025
work_keys_str_mv AT ishidanatsuki lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT asaiyusuke lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT miyazutakahiro lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT tamurasatoshi lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT tanishinya lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT yamademihoko lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT iwaizumimoriya lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT hamayayasushi lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT osawasatoshi lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT furutatakahisa lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy
AT sugimotoken lymphocytetomonocyteratioisashorttermpredictivemarkerofulcerativecolitisafterinductionofadvancedtherapy